Panel Embraces Sanofi Diabetes Combo, Shuns 'Pen' Devices

While the FDA's Endocrinologic and Metabolic Drugs Advisory Committee backed approval of Sanofi SA's fixed-ratio combination type 2 diabetes medicine, many of the panelists objected to the two complicated pen devices the company is proposing to use to administer the drug – calling for them to be redesigned.